Dr. Deirdre Cohen talks about the increasingly big role of immunotherapies in the treatment of patients with gastric cancers.
Deirdre Cohen, MD, assistant professor of medicine, NYU Langone's Laura and Isaac Perlmutter Cancer Center, talks about the increasingly big role of immunotherapies in the treatment of patients with gastric cancers. Cohen says single agents used in patients with the subtype of gastric cancer that show higher levels of PD-L1 and PD-L2 expression, will most likely get the most benefit out of treatment.
Cohen adds that immunotherpies used in conjunction with other agents are more likely to be useful in the treatment of other types of gastric cancer outside those showcasing PD-L1 and PD-L2 expression. She also notes that according to the TCGA classifications, there are four subtypes of gastric cancers.
Combining Avutometinib With Defactinib Yields High Response Rates in LGSOC
March 22nd 2024In heavily pretreated patients with recurrent low-grade serous ovarian cancer, the combination of avutometinib plus defactinib showing promising results within the phase 2 ENGOT-ov60/GOG-3052/RAMP 201 trial.
Read More
The Impact of the Gut Microbiome in Young Patients With Colorectal Cancer
February 15th 2021In season 2, episode 2 of Targeted Talks, Cathy Eng, MD, speaks with Benjamin Weinberg, MD, about the gut microbiome, and how the presence of certain microbiota impact the onset and intensity of disease as well as the potential response to certain treatments.
Listen
Ixabepilone/Bevacizumab Improves PFS and OS in Platinum-Resistant/Refractory Ovarian Cancer
March 19th 2024Combining ixabepilone with bevacizumab generated improved survival rates and high response rates compared with ixabepilone monotherapy in platinum-resistant or platinum-refractory ovarian cancer.
Read More